Affitech appoints cfo

Stig Jarle Pettersen was formerly a consultant to the Danish antibody medicines firm

Affitech, a Danish antibody medicines company, has appointed Stig Jarle Pettersen as chief financial officer.

Pettersen will be a member of the executive management of Affitech with managing director Martin Welschof and chief scientific officer Alexander Duncan.

Pettersen is a Norwegian state authorised public accountant with more than 20 years of experience at Hafslund Nycomed, Helicopter Services Group, Alpharma, Actavis and most recently as chief financial officer at Xellia Pharmaceuticals.

Pettersen worked as a consultant for Affitech in September 2009 and participated in the process of restructuring and refinancing the company. He now joins the company when, due to investment by TransNova in April, it is able to finance the further development of its two leading drug candidates in collaboration with NTSPlus of Russia.

Affitech expects to file a Clinical Trial Application in 2011 for its anti-VEGF antibody AT001/r84, whose main indication is for anti-angiogenesis treatment in several cancers.

You may also like

Research & Development

Applied Biopharm Consulting awarded Innovation funding to validate AI-powered AAV vector engineering platform

Irish biotech consultancy Applied Biopharm Consulting has secured an Innovation Voucher from the Local Enterprise Office Cork North & West to collaborate with an academic partner in validating its computational platform for adeno-associated virus vector optimisation through laboratory testing
Manufacturing

L.B. Bohle hosts successful continuous manufacturing workshop in Brazil

Focus on continuous wet granulation and drying for research, development and small-scale production
Manufacturing

Swiss Rockets collaborates with Lonza to advance Torqur’s oncology drug candidate bimiralisib into late-stage clinical development

Lonza to provide cGMP manufacturing and technical support to advance bimiralisib into late-stage clinical development
Research & Development

Phesi analysis finds 6.7% of global clinical trials affected by Middle East disruption

A Phesi analysis of more than 65,000 active clinical trials has found that 4361 studies are impacted by Middle East disruption, with Phase III oncology trials most exposed and all top ten global pharma companies holding significant investigator site presence in affected countries
Manufacturing

Degasser for volatile and aggressive solvents

Biotech Fluidics announce the DEGASi Integration HFIP - a high-performance online system designed to efficiently degas even the toughest solvents. This unique degasser is fully compatible with a wide range of volatile and aggressive liquids including Hexafluoroisopropanol (HFIP) and silanes but can also manage all other solvents used for GPC/SEC and HPLC
Research & Development

Symeres joins forces with Ambagon Therapeutics to expand molecular glue research in colorectal cancer

The pair will aim to explore a new class of small molecules, known as molecular glues, for potential therapeutic use in colorectal cancer and other hard-to-target diseases as an alternative to traditional therapies
Research & Development

University of Exeter leads £4.5m Wellcome-funded initiative to develop bioimaging tools for fungal pathogens

An international collaboration spanning the universities of Exeter, Edinburgh and Cape Town has secured £4.5m to develop specialist bioimaging tools for WHO-priority fungal pathogens
Subscribe now